Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.35 |
| ▸ | AVPR1A | P37288 | 7/20 | 0.34 |
| ▸ | OXTR | P30559 | 2/20 | 0.34 |
| ▸ | FPR2 | P25090 | 2/20 | 0.33 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.33 |
| ▸ | HRH1 | P35367 | 3/20 | 0.33 |
| ▸ | CCR3 | P51677 | 3/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30553154 | 1.00 | EPHX2 (0.38) | EPHX2ENPP2ATXN2AVPR1AOXTR | |
| SCHEMBL25324849 | 0.85 | SCN9A (0.36) | EPHX2SCN9A | |
| SCHEMBL25324615 | 0.82 | ENPP2 (0.39) | ENPP2ATXN2AVPR1AOXTR | |
| SCHEMBL30700515 | 0.81 | EPHX2 (0.38) | EPHX2ENPP2ATXN2FPR2PROKR1 | |
| SCHEMBL25326047 | 0.79 | ENPP2 (0.39) | ENPP2ATXN2AVPR1AOXTR | |
| SCHEMBL25325397 | 0.79 | CHRM4 (0.34) | AVPR1AOXTR | |
| SCHEMBL30409744 | 0.78 | MGLL (0.40) | EPHX2 | |
| SCHEMBL25145744 | 0.78 | MGLL (0.40) | EPHX2 | |
| SCHEMBL25326743 | 0.78 | ENPP2 (0.43) | EPHX2ENPP2ATXN2AVPR1AOXTR | |
| SCHEMBL25325348 | 0.77 | ABHD6 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | claimed |
| WO-2023144160-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-03 | — | — | WO | claimed |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| WO-2023144160-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | EPHX2 292/4885ENPP2 3934/4885ATXN2 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.